Education
About Us
Working with TipRanks
Follow Us
Peter Salzmann Insider Profile
11 Followers
Peter Salzmann, CEO, Director at Immunovant, holds 1.18M shares in Immunovant (Ticker: IMVT), holds 2.78K shares in Corbus Pharmaceuticals (Ticker: CRBP). Most recently, Peter Salzmann Sold ― shares of Immunovant on Apr 17, 2025 for an estimated value of 123.90K.
Profitable Transactions
16 out of 33 Profitable Transactions
Average Return
-88.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Peter Salzmann holds in companies
Most Profitable Insider Trade
The most profitable trade made by Peter Salzmann
Peter Salzmann's Trading History
Immunovant
Apr 17, 2025
CEO, Director
Informative Sell
123.90K
$19.97M
Corbus Pharmaceuticals
Jun 03, 2024
Director
Uninformative Buy
―
$25.77K
List of latest transactions for each holding click on a transaction to see Peter Salzmann's performance on stock
You May Also Like
Peter Salzmann insider profile FAQ
What is the percentage of profitable transactions made by Peter Salzmann?
The percentage of profitable transactions made by Peter Salzmann is 48%.
What is the average return per transaction made by Peter Salzmann?
The average return per transaction made by Peter Salzmann is -88.60%.
What stocks does Peter Salzmann hold?
Peter Salzmann holds: IMVT, CRBP stocks.
What was Peter Salzmann’s latest transaction?
Peter Salzmann latest transaction was an Informative Sell of $123.90K.
What was Peter Salzmann's most profitable transaction?
Peter Salzmann’s most profitable transaction was an Informative Sell of IMVT stock on April 10, 2024. The return on the trade was 52.10%.
What is Peter Salzmann's role in Immunovant?
Peter Salzmann's role in Immunovant is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.